400737-27-1

Basic information

• Product Name: Butanal, 4-methoxy-3-[(4-methoxyphenyl)methoxy]-, (3R)-
• CAS NO: 400737-27-1
• Molecular Formula: C13H18O4
• Molecular Weight: 238.284
• Mol File: 400737-27-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Butanal, 4-methoxy-3-[(4-methoxyphenyl)methoxy]-, (3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanal, 4-methoxy-3-[(4-methoxyphenyl)methoxy]-, (3R)-(400737-27-1)
• EPA Substance Registry System: Butanal, 4-methoxy-3-[(4-methoxyphenyl)methoxy]-, (3R)-(400737-27-1)

Safety Data

• Hazardous Substances Data: 400737-27-1(Hazardous Substances Data)

Upstream product

• 400737-20-4 (R)-1-[1,3]Dithian-2-yl-3-methoxy-propan-2-ol 
• 400737-23-7 2-[(R)-3-Methoxy-2-(4-methoxy-benzyloxy)-propyl]-[1,3]dithiane 

Downstream Products

• 400737-36-2 (2S,3R,5R)-3-(tert-Butyl-dimethyl-silanyloxy)-6-methoxy-5-(4-methoxy-benzyloxy)-2-methyl-hexanal 
• 400737-33-9 tert-Butyl-{(1R,2R)-1-[(R)-3-methoxy-2-(4-methoxy-benzyloxy)-propyl]-2-methyl-but-3-enyloxy}-dimethyl-silane 
• 400737-40-8 (R)-4-Benzyl-3-[(2R,3S,4R,5R,7R)-5-(tert-butyl-dimethyl-silanyloxy)-3-hydroxy-8-methoxy-7-(4-methoxy-benzyloxy)-2,4-dimethyl-octanoyl]-oxazolidin-2-one 
• 1449419-44-6 C₃₅H₄₆O₈ 
• 1449419-32-2 C₄₁H₆₂O₉Si 
• 1449419-29-7 C₄₄H₅₈O₈ 
• 1449419-26-4 C₁₃H₁₈O₅ 
• 1449419-16-2 C₂₈H₄₀O₈ 
• 1449419-41-3 C₃₅H₄₈O₉ 
• 1449419-38-8 C₄₂H₆₄O₇Si 
• 1449419-35-5 C₃₆H₅₀O₇ 
• 400736-37-0 2-[(1R,2S,3S,4R,6R)-2,4-Bis-(tert-butyl-dimethyl-silanyloxy)-7-methoxy-6-(4-methoxy-benzyloxy)-1,3-dimethyl-heptyl]-[1,3]dithiane 
• 400737-46-4 (2R,3S,4S,5R,7R)-5-(tert-Butyl-dimethyl-silanyloxy)-8-methoxy-7-(4-methoxy-benzyloxy)-2,4-dimethyl-3-trimethylsilanyloxy-octanoic acid methoxy-methyl-amide 
• 400737-43-1 (2R,3S,4R,5R,7R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-hydroxy-8-methoxy-7-(4-methoxy-benzyloxy)-2,4-dimethyl-octanoic acid methoxy-methyl-amide 

Relevant articles and documents

Antitumor drugs and methods

Derivatives of apoptolidin, including skeletal homologues, are potent and selective apoptosis-inducing agents which, unlike apoptolidin, do not undergo isomerization under physiological conditions. These compounds exhibit antitumor properties, often superior to those of apoptolidin, and as such can be used in the treatment of cancer and other hyperproliferative disorders.

Total synthesis of apoptolidin: Part 1. Retrosynthetic analysis and construction of building blocks

No less than 30 stereogenic elements, a highly unsaturated 20-membered macrocyclic system, four carbohydrate units, and unique biological activity, make the natural occurring apoptolidin (1) a challenging synthetic target. The retrosynthetic analysis reve